Right To Try
Congress has finally passed the Right to Try Act, but does it go far enough?
It's still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.
The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.